Bristol Myers Squibb Reports Q4 Profit Up 12% to $1.8B, Misses by $0.03

Bristol Myers Squibb Co. (BMY) reported fourth-quarter net profit of $1.8B, up 12% from $1.6B in the same period of 2025, on February 5, 2026. Revenue for the quarter totaled $10.2B, a 6% increase year-over-year. The company missed the average estimate of $1.83B by $0.03 per share due to higher-than-expected research and development costs and pricing pressures on key oncology products. Management attributed the profit growth to higher sales of opdivo and other immuno-oncology therapies and favorable manufacturing productivity.